Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
03 January 2022 - 11:00PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Scott Harris, Chief Medical
Officer at Altimmune, will give an oral and a poster presentation
on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon
dual receptor agonist under development for the treatment of
obesity and non-alcoholic steatohepatitis (NASH), the most severe
form of non-alcoholic fatty liver disease (NAFLD). The
presentations will take place at the NASH-TAG Conference, which is
being held January 6-8, 2022, in Park City, Utah. Details for the
oral presentation are as follows:
Title: |
A placebo-controlled, double-blind, first-in-human study of
Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist
for the treatment of NASH and obesity |
Presenter: |
Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
Date/Time: |
Saturday, January 8, 2022 at 8:10 am Mountain Time |
A copy of Dr. Harris’ presentation and poster will be accessible
on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical
company focused on developing treatments for obesity and liver
diseases. Our pipeline includes next generation peptide
therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis
B (HepTcell™). For more information, please visit
www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media Contacts:
Richard EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2024 to May 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From May 2023 to May 2024